Identification of acridinedione scaffolds as potential inhibitor of DENV‐2 C protein: An in silico strategy to combat dengue. Issue 5 (21st March 2022)

• Record Type: Journal Article
• Authors: Kumar, Sachin; Bhardwaj, Vijay K.; Singh, Rahul; Das, Pralay; Purohit, Rituraj
• Is Part Of: Journal of cellular biochemistry. Volume 123:Issue 5(2022)
• Page Start: 935
• Page End: 946
• Publication Date: 2022-03-21
• Subjects: acridinedione analogs -- capsid protein -- dengue -- MD simulations -- molecular docking -- umbrella sampling; Cytochemistry -- Periodicals; 572
• DOI: 10.1002/jcb.30237
• Languages: English
• ISSNs: 0730-2312

Abstract

Abstract: Dengue is a prominent viral disease transmitted by mosquitoes to humans that affects mainly tropical and subtropical countries worldwide. The global spread of dengue virus (DENV) is mainly occurred by Aedes aegypti and Aedes albopictus mosquitoes. The dengue virus serotypes‐2 (DENV‐2) is a widely prevalent serotype of DENV, that causes the hemorrhagic fever and bleeding in the mucosa, which can be fatal. In the life cycle of DENV‐2, a structural capsid (DENV‐2 C) protein forms the nucleocapsid assembly and bind to the viral progeny RNA. For DENV‐2 maturation, the nucleocapsid is a vital component. We used virtual ligand screening to filter out the best in‐house synthesized acridinedione analogs (DSPD molecules) that could efficiently bind to DENV‐2 C protein. The molecular docking and dynamics simulations studies were performed to analyze the effect of DSPD molecules on DENV‐2 C protein after binding. Our findings showed that DSPD molecules strongly interacted with DENV‐2 C protein, as evident from molecular interactions and several time‐dependent molecular dynamics‐driven analyses. Moreover, this study was also supported by the thermodynamic binding free energy and steered molecular dynamics simulations. Therefore, we intend to suggest that the DSPD3 molecule could be used as a potential therapeutic molecule against dengue complications as compared to the cocrystallized inhibitor ST‐148. However, further studies are required to demonstrate the ability of DSPD3 to induce DENV‐2 C tetramer formation.